Cohance Lifesciences charts growth path with acquisitions and transformation

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, announced its Seventh Annual General Meeting (AGM) for September 19, 2025, to review its Annual Report 2024-25. The company's name change, effective May 7, 2025, reflects its transformation into a technology-led global CDMO. A key highlight is the acquisition of Sapala Organics Private Limited and NJ Bio Inc., significantly expanding capabilities in Antibody Drug Conjugates (ADCs) and oligonucleotides. The company aims for $1 billion in global revenue by 2030, driven by a higher share of CDMO and niche technologies.

Financially, Cohance reported a consolidated revenue from operations of ₹1,197.58 Crores for FY2024-25, a 14% increase from the previous year. Profit after tax declined by 12% to ₹264.77 Crores due to integration costs. The company's ESG initiatives include reducing absolute Scope 1 & 2 emissions by 35% by 2030 and transitioning to renewable energy sources for at least 20% of total energy use by 2027. Remuneration for key managerial personnel was approved, with Dr. V. Prasada Raju re-appointed as managing director.